Hantavirus treatment begins the moment a patient arrives at an emergency department — not when a test result returns. Because there is no approved antiviral for Hantavirus Pulmonary Syndrome (HPS), every clinical decision is about support: keeping the patient alive long enough for their immune system to clear the virus.
Understanding how hantavirus is treated is not academic. It has direct survival implications for patients, families, and clinicians who may not see HPS regularly.
Why There Is No Specific Antiviral
Unlike influenza (where oseltamivir reduces severity) or COVID-19 (where antivirals like nirmatrelvir exist), no drug has proven effective at reducing hantavirus severity or mortality in clinical trials.
Ribavirin has been tested for HPS and is used in some HFRS (hemorrhagic fever with renal syndrome) settings, but trial data for HPS — particularly for Andes and Sin Nombre virus — has not confirmed a clear mortality benefit.
This means the ICU team’s toolkit is:
- oxygen and respiratory support,
- hemodynamic stabilization,
- fluid management (carefully — too much worsens pulmonary edema),
- vasopressors for refractory shock,
- ECMO in extreme cases.
ER Triage: What Happens First
When a patient presents with fever, severe myalgia, and possible rodent or Hondius-linked exposure, fast categorization matters.
Triage priorities:
- Capture exposure history immediately — rodent contact, travel, cruise ship link.
- Baseline vitals and oxygen saturation — oxygen demand is an early prognostic signal.
- Blood work: CBC (platelet count, hematocrit), chemistry, lactate, inflammatory markers.
- Chest X-ray: bilateral interstitial infiltrates can appear even before significant respiratory distress.
- Collect RT-PCR and initial serology for hantavirus testing.
The key mistake in low-incidence settings: anchoring on influenza or COVID-19 as the working diagnosis before ruling out hantavirus in a high-risk exposure context.
The Warning Transition: Prodrome to Cardiopulmonary Phase
HPS moves through two clinical phases:
Prodrome: 2–7 days of fever, fatigue, headache, severe myalgia. Looks like flu.
Cardiopulmonary phase: Sudden onset of cough, dyspnea, and rapidly worsening respiratory failure. Pulmonary edema develops within hours. This is the window where ICU transfer decisions become life-or-death.
Critically: patients in the prodrome phase can deteriorate very rapidly. The clinical rule is transfer to a high-acuity setting before the cardiopulmonary phase begins — not after respiratory failure is already present.
ICU Management: What Keeps Patients Alive
Oxygen Strategy
Non-invasive oxygen support is tried first if the patient can protect their airway. High-flow nasal cannula (HFNC) may be used. Intubation and mechanical ventilation are often necessary as disease progresses.
Lung-protective ventilation is standard: low tidal volumes, controlled plateau pressures to reduce further barotrauma to already-damaged pulmonary tissue.
Hemodynamic Support
Capillary leak in HPS causes fluid shifts that compromise cardiac output. Vasopressors (norepinephrine, vasopressin) are often required. Central venous monitoring guides fluid decisions carefully — overly aggressive fluid replacement worsens pulmonary edema.
ECMO: Last Escalation
For patients who fail mechanical ventilation — cardiac index dropping, refractory hypoxia — ECMO (extracorporeal membrane oxygenation) is the last escalation. ECMO buys time while the acute viral phase resolves.
Survival rates with ECMO in HPS range from roughly 30–55% depending on center experience and patient selection. It is resource-intensive and not available at all hospitals.
In the MV Hondius cluster, several European cases received ECMO support. The availability of ECMO at major European centers is significantly higher than in rural South American areas where Andes HPS has historically occurred.
What Determines Survival
Published data across multiple case series identifies several consistent predictors:
Better prognosis:
- Early hospital presentation (still in prodrome)
- Transfer to ICU before cardiac collapse
- Young age (under 40 has roughly half the CFR of over 60)
- No pre-existing cardiovascular disease
- Center with ECMO capability
Worse prognosis:
- Presentation in respiratory failure
- Rapid bilateral infiltrates on admission X-ray
- Hematocrit >45% (severe hemoconcentration)
- Platelet count <100,000/μL on arrival
- Low cardiac index early in cardiopulmonary phase
What Families Should Understand
If a family member is hospitalized for suspected or confirmed HPS:
- Isolation is standard — not because you are at risk from ordinary contact, but to enable controlled monitoring.
- Deterioration can be fast — the window from symptom onset to ICU can be 24–48 hours.
- Asking about ECMO availability at your hospital is reasonable if the patient is progressing despite conventional ICU support.
- No antiviral exists that you can demand or obtain — treatment really is supportive, and the hospital team is doing the right things.
The 2026 Hondius Clinical Context
The Hondius cluster has provided European hospital systems with their first modern experience managing imported Andes virus HPS at scale. Multiple cases across the Netherlands, France, Germany, Switzerland, Italy, and the UK required varying levels of ICU support, including ECMO in several patients.
The outcomes (3 deaths out of 17 cases, roughly 18% CFR) are somewhat lower than baseline Andes HPS epidemiological data from Argentina (35–40%), likely reflecting the advantage of early identification, rapid transfer to specialized centers, and ECMO availability.
This underscores what the literature already shows: where and how fast a patient is treated matters as much as the biology of the virus.
Track current Hondius case outcomes: Global Hantavirus Map
Explore HantavirusMap